Hafey M - Search Results

1

Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.

He H, Lyons KA, Shen X, Yao Z, Bleasby K, Chan G, Hafey M, Li X, Xu S, Salituro GM, Cohen LH, Tang W. He H, et al. Among authors: hafey m. Xenobiotica. 2009 Sep;39(9):687-93. doi: 10.1080/00498250903015402. Xenobiotica. 2009. PMID: 19569734

2

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG. Bleasby K, et al. Among authors: hafey mj. Xenobiotica. 2006 Oct-Nov;36(10-11):963-88. doi: 10.1080/00498250600861751. Xenobiotica. 2006. PMID: 17118916

3

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Chu XY, et al. J Pharmacol Exp Ther. 2007 May;321(2):673-83. doi: 10.1124/jpet.106.116517. Epub 2007 Feb 21. J Pharmacol Exp Ther. 2007. PMID: 17314201

4

Madin-Darby canine kidney II cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake.

Weinglass AB, Köhler MG, Nketiah EO, Liu J, Schmalhofer W, Thomas A, Williams B, Beers L, Smith L, Hafey M, Bleasby K, Leone J, Tang YS, Braun M, Ujjainwalla F, McCann ME, Kaczorowski GJ, Garcia ML. Weinglass AB, et al. Among authors: hafey m. Mol Pharmacol. 2008 Apr;73(4):1072-84. doi: 10.1124/mol.107.043844. Epub 2008 Jan 10. Mol Pharmacol. 2008. PMID: 18187582

5

Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats.

Tang W, Stearns RA, Chen Q, Bleasby K, Teffera Y, Colletti A, Hafey M, Evers R, Dean DC, Magriotis PA, Lanza TJ, Lin LS, Hagmann WK, Baillie TA. Tang W, et al. Among authors: hafey m. Xenobiotica. 2008 Feb;38(2):223-37. doi: 10.1080/00498250701744682. Xenobiotica. 2008. PMID: 18197560

6

Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.

Lévesque JF, Bleasby K, Chefson A, Chen A, Dubé D, Ducharme Y, Fournier PA, Gagné S, Gallant M, Grimm E, Hafey M, Han Y, Houle R, Lacombe P, Laliberté S, MacDonald D, Mackay B, Papp R, Tschirret-Guth R. Lévesque JF, et al. Among authors: hafey m. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5547-51. doi: 10.1016/j.bmcl.2011.06.095. Epub 2011 Jun 28. Bioorg Med Chem Lett. 2011. PMID: 21784634

7

Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X. Rizk ML, et al. Among authors: hafey m. Antimicrob Agents Chemother. 2014;58(3):1294-301. doi: 10.1128/AAC.02049-13. Epub 2013 Dec 2. Antimicrob Agents Chemother. 2014. PMID: 24295974 Free PMC article.

8

Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters.

Bleasby K, Houle R, Hafey M, Lin M, Guo J, Lu B, Sanchez RI, Fillgrove KL. Bleasby K, et al. Among authors: hafey m. Viruses. 2021 Aug 7;13(8):1566. doi: 10.3390/v13081566. Viruses. 2021. PMID: 34452431 Free PMC article.

9

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, Du X, Gordon R, Guay J, Guiral S, Hafey MJ, Hamelin E, Huang Z, Kennedy B, Lachance N, Landry F, Li CS, Mancini J, Normandin D, Pocai A, Powell DA, Ramtohul YK, Skorey K, Sørensen D, Sturkenboom W, Styhler A, Waddleton DM, Wang H, Wong S, Xu L, Zhang L. Oballa RM, et al. Among authors: hafey mj. J Med Chem. 2011 Jul 28;54(14):5082-96. doi: 10.1021/jm200319u. Epub 2011 Jun 28. J Med Chem. 2011. PMID: 21661758

10

Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.

Powell DA, Black WC, Bleasby K, Chan CC, Deschenes D, Gagnon M, Gordon R, Guay J, Guiral S, Hafey MJ, Huang Z, Isabel E, Leblanc Y, Styhler A, Xu LJ, Zhang L, Oballa RM. Powell DA, et al. Among authors: hafey mj. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7281-6. doi: 10.1016/j.bmcl.2011.10.040. Epub 2011 Oct 18. Bioorg Med Chem Lett. 2011. PMID: 22047692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page